There are currently 675 ongoing clinical trials involving Anemia
Of the 675 trials,241 trials are in Phase II
Furthermore, 136 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Anemia, a Hematological disorder. The highest number of ongoing clinical trials involving Anemia is in North America. Asia-Pacific and Europe are among some of the other prominent regions involved in Anemia-related drug trials.
National Heart Lung and Blood Institute: The leading ongoing Anemia-related clinical trials sponsor
National Heart Lung and Blood Institute, the United States of America-based government institute, is the top sponsor for Anemia-related ongoing clinical trials.
Novartis AG, Global Blood Therapeutics Inc, Cincinnati Children's Hospital Medical Center, Celgene Corp, and Institute of Hematology & Blood Diseases Hospital are a few other notable sponsors involving Anemia.
A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Anemia
Eltrombopag olamine (Revolade/ Promacta/ Revoleyd/ Rebozet, Darbepoetin alfa (Aranesp PFS/ Aranesp SureClick/ NESP/ Angevour ), and Romiplostim (Nplate) are among the key marketed drugs involving Anemia.
Eltrombopag olamine (Revolade/ Promacta/ Revoleyd/ Rebozet) is a small molecule, nonpeptide thrombopoietin receptor agonist. It functions via the Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Agonist. It is formulated as film-coated tablets and powder for suspension for the oral route of administration. Promacta is indicated for the treatment of thrombocytopenia in patients with chronichepatitis C to allow the initiation and maintenance of interferon-based therapy, for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who has had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag olamine was first approved in 2008 and is marketed globally including the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including Novartis AG.
Darbepoetin alfa (Aranesp PFS/ Aranesp SureClick/ NESP/ Angevour ) is a recombinant human protein that acts as a hemopoietic agent closely related to erythropoietin. It functions via Erythropoietin Receptor (EPOR) Agonist mechanism of action. It is formulated as a solution. Darbepoetin alfa is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. It is also indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy. In Japan, it is also approved for the treatment of anemia in myelodysplastic syndrome. Darbepoetin alfa was first approved in 2001 and is marketed globally including the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including Amgen Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer